In another study, Li et al. developed FM@PFC nanoemulsions containing a CXCR4 antagonist and anti-STAT3 siRNA, showing that pulmonary delivery of these nanoemulsions reduced tumor invasion, angiogenesis, and immunosuppression while inducing apoptosis, demonstrating a novel approach to improving lung metastasis therapy (Li et al., 2019). This evidence concerns the gene CXCR4 and neoplasm.